XLO Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -85.42% compared to Xilio Therapeutics, Inc.'s net margin of -255.85%. Xilio Therapeutics, Inc.'s return on equity of -606.15% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Xilio Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 194.12%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -95.56%. Given that Xilio Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Xilio Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Xilio Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Xilio Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Xilio Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Xilio Therapeutics, Inc. quarterly revenues are $19.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Xilio Therapeutics, Inc.'s net income of -$16.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Xilio Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 32.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xilio Therapeutics, Inc. is 2.03x versus 37.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics, Inc. has a net margin of -85.42% compared to Xilio Therapeutics, Inc.'s net margin of --. Xilio Therapeutics, Inc.'s return on equity of -606.15% beat Oragenics, Inc.'s return on equity of -509.23%.

Xilio Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 194.12%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 140.65%. Given that Xilio Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Xilio Therapeutics, Inc. is more attractive than Oragenics, Inc..

Xilio Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.

Xilio Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xilio Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Xilio Therapeutics, Inc. quarterly revenues are $19.1M, which are larger than Oragenics, Inc. quarterly revenues of --. Xilio Therapeutics, Inc.'s net income of -$16.3M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Xilio Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xilio Therapeutics, Inc. is 2.03x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -85.42% compared to Xilio Therapeutics, Inc.'s net margin of --. Xilio Therapeutics, Inc.'s return on equity of -606.15% beat Palatin Technologies's return on equity of --.

Xilio Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 194.12%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Xilio Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Xilio Therapeutics, Inc..

Xilio Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Xilio Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xilio Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Xilio Therapeutics, Inc. quarterly revenues are $19.1M, which are larger than Palatin Technologies quarterly revenues of --. Xilio Therapeutics, Inc.'s net income of -$16.3M is higher than Palatin Technologies's net income of --. Notably, Xilio Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xilio Therapeutics, Inc. is 2.03x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -85.42% compared to Xilio Therapeutics, Inc.'s net margin of --. Xilio Therapeutics, Inc.'s return on equity of -606.15% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Xilio Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 194.12%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3158.85%. Given that Theriva Biologics, Inc. has higher upside potential than Xilio Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Xilio Therapeutics, Inc..

Xilio Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.

Xilio Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xilio Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Xilio Therapeutics, Inc. quarterly revenues are $19.1M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Xilio Therapeutics, Inc.'s net income of -$16.3M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Xilio Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xilio Therapeutics, Inc. is 2.03x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.